Clinical Trial Update: Study of a Retroviral Replicating Vector Given Intravenously to Patients Undergoing Surgery for Recurrent Brain Tumor [Phase 1]

View source ↗

Summary

This document reports the completion of a Phase 1 trial evaluating a retroviral replicating vector (Toca 511) given intravenously to patients undergoing surgery…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Astrocytoma
• Anaplastic Oligoastrocytoma
• Anaplastic Oligodendroglioma
• Glioblastoma Multiforme

Drugs mentioned

• Toca 511 (retroviral replicating vector expressing cytosine deaminase)

Snippet

Sponsor: Tocagen Inc. | Conditions: Glioblastoma Multiforme, Anaplastic Astrocytoma | Phase 1 | Status: COMPLETED